Chronic Pancreatitis Pain Pipeline, Clinical Trials, and Emerging Therapies Report 2023 | Key Companies- First Wave BioPharma Inc, Calcimedica, Theraly Fibrosis, and Others

DelveInsight's, "Chronic Pancreatitis Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+pipeline drugs in the chronic pancreatitis pipeline landscape. It covers the Chronic Pancreatitis pipeline drug profiles, including Chronic Pancreatitis clinical trials and nonclinical stage products. It also covers the Chronic Pancreatitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Pancreatitis Pain Pipeline Report

• DelveInsight's Chronic Pancreatitis Pain Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Chronic Pancreatitis Pain treatment.

• The leading Chronic Pancreatitis Pain Companies include First Wave BioPharma, Inc., Calcimedica, Theraly Fibrosis, TAP Pharmaceutical Products Inc., and others

• Promising Chronic Pancreatitis Pain Pipeline Therapies include Triamcinolone, Bupivicaine alone, FW-EPI (adrulipase), CM4620, and others

• The Chronic Pancreatitis Pain companies and academics are working to assess challenges and seek opportunities that could influence chronic pancreatitis R&D. The Chronic Pancreatitis Pain therapies under development are focused on novel approaches to treat/improve chronic pancreatitis.

Request a sample and discover the recent breakthroughs happening in the Chronic Pancreatitis Pain Pipeline landscape @ Chronic Pancreatitis Pain Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-pancreatitis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Pancreatitis Pain Overview
Chronic pancreatitis is a condition where the pancreas (a small organ located behind the stomach and below the ribcage) becomes permanently damaged from inflammation. It is a progressive inflammatory disorder that leads to irreversible destruction of exocrine and endocrine pancreatic parenchyma caused by atrophy and/or replacement with fibrotic tissue.

Chronic Pancreatitis Pain Emerging Drugs Profile

• FW-EPI (adrulipase): First Wave BioPharma, Inc.
FW-EPI (adrulipase) is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. Adrulipase is derived from the Yarrowia lipolytica yeast lipase and is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients. First Wave is developing adrulipase as a monotherapy and in combination with pancreatic enzyme replacement therapy (PERT). The drug is in Phase II clinical trial of adrulipase in combination with PERT.

• CM4620: calcimedica
CM4620, a novel, calcium release-activated calcium (CRAC) channel inhibitor administered orally. The drug is in pre-clinical stage for the treatment of Chronic Pancreatitis.

For further information, refer to the detailed Chronic Pancreatitis Pain Drugs Launch, Chronic Pancreatitis Pain Developmental Activities, and Chronic Pancreatitis Pain News, click here for Chronic Pancreatitis Pain Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-pancreatitis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Pancreatitis Pain Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for chronic pancreatitis. The companies which have their chronic pancreatitis drug candidates in the most advanced stage, i.e. phase II include, First Wave BioPharma, Inc.

Chronic Pancreatitis Pain Pipeline Segmentation

Phases
DelveInsight's report covers around 5+products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Chronic pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Find out more about the Chronic Pancreatitis Pain Pipeline Segmentation, Therapeutics Assessment, and Chronic Pancreatitis Pain Emerging Drugs @ Chronic Pancreatitis Pain Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-pancreatitis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Pancreatitis Pain Pipeline Report

• Coverage- Global

• Chronic Pancreatitis Pain Companies- First Wave BioPharma, Inc., Calcimedica, Theraly Fibrosis, TAP Pharmaceutical Products Inc., and others

• Chronic Pancreatitis Pain Pipeline Therapies- Triamcinolone, Bupivicaine alone, FW-EPI (adrulipase), CM4620, and others

• Chronic Pancreatitis Pain Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Chronic Pancreatitis Pain Pipeline Companies and Therapies, click here @ Chronic Pancreatitis Pain Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-pancreatitis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic pancreatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic pancreatitis- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. FW-EPI (adrulipase): First Wave BioPharma, Inc.
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. TLY012: Theraly Fibrosis
12. Drug profiles in the detailed report…..
13. Preclinical and Discovery Stage Products
14. CM4620: calcimedica
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Chronic pancreatitis Key Companies
18. Chronic pancreatitis Key Products
19. Chronic pancreatitis- Unmet Needs
20. Chronic pancreatitis- Market Drivers and Barriers
21. Chronic pancreatitis- Future Perspectives and Conclusion
22. Chronic pancreatitis Analyst Views
23. Chronic pancreatitis Key Companies
24. Appendix

Got Queries? Find out the related information on Chronic Pancreatitis Pain Mergers and acquisitions, Chronic Pancreatitis Pain Licensing Activities @ Chronic Pancreatitis Pain Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/chronic-pancreatitis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.